The CE mark will take what it takes but the real win will come with the results of the trials, PanCO and OncoPaC-1. Making a realistic chance of recovery from Pancreatic Cancer (PC) will be the dramatic leverage. See the Annual Report. Currently PC has only a 1% chance of recovery with a 5% chance of surviving 5 years. What this device is looking like doing, providing a real %age chance of not only surviving longer but full recovery for others, will make this device invaluable and testable for a whole range of cancers. If it takes a few months to get there, who cares.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9286 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 412 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |